A review on the use of corticosteroids

  • Sushrutha Kanaparthi Doctor of pharmacy
Keywords: Corticosteroids, Glucocorticoid receptors, Management, Side effects,, Tapering


corticosteroids [CS] are used to treat various diseased conditions such as inflammatory diseases including allergic diseases and hypersensitivity reactions. Cortisol is produced in the adrenal gland and a variety of other hormones are produced through cholesterol metabolism. They are elaborated in the regulation of different processes such as metabolism electrolyte regulation inflammation, and stress responses based on their major effects. Corticosteroids acts as anti-inflammatory, antiproliferative, immunosuppressive and shows vasoconstrictive effects. Prolonged use of  corticosteroid leads to hormonal changes within the body which may cause a wide range of side effects. Once corticosteroids are prescribed the patient should be monitored regularly and reviewed to assess the response to the treatment with adjusting the dose at a minimum. When corticosteroids are used thoroughly as intensive therapy or for prolonged courses, a tapering strategy is recommended to prevent signs and symptoms of adrenal insufficiency due to hypothalamic-pituitary-adrenal axis suppression.


Download data is not yet available.


Baeck M, Marot L, Nicolas JF, Pilette C, Tennstedt D, Goossens A. Allergic hypersensitivity to topical and systemic corticosteroids: a review. Allergy. 2009 Jul;64(7):978-94.

Roth P, Happold C, Weller M. Corticosteroid use in neuro-oncology: an update. Neuro-oncology practice. 2015 Mar 1;2(1):6-12.

Williams DM. Clinical pharmacology of corticosteroids. Respiratory care. 2018 Jun 1;63(6):655-70.

Van Staa TP, Leufkens HG, Abenhaim L, Begaud B, Zhang B, Cooper C. Use of oral corticosteroids in the United Kingdom. Qjm. 2000 Feb 1;93(2):105-11.

Manson SC, Brown RE, Cerulli A, Vidaurre CF. The cumulative burden of oral corticosteroid side effects and the economic implications of steroid use. Respiratory medicine. 2009 Jul 1;103(7):975-94.

Hengge UR, Ruzicka T, Schwartz RA, Cork MJ. Adverse effects of topical glucocorticosteroids. Journal of the American Academy of Dermatology. 2006 Jan 1;54(1):1-5.

Hench PS, Kendall EC, Slocumb CH,Polley HF. The effect of a hormone of the adrenal cortex (17-hydroxy-11dehydrocorticosterone:compound E) and of pituitary adrenocorticotropic hormone on rheumatic arthritis. Proc Staff Meet Mayo Clin 1949;24:181.

Sulzberger MB, Witten VH. Preliminary and short reports. The effect of topically applied compound F in selected dermatoses. J Invest Dermatol 1952;19:101–102.

Stevenson. H.C.; Fauci, A.S.: Effects of corticosteroids on the function and distribution of human lymphocytes; in Franklin, Clinical immunology update, reviews for physicians, pp. 337— 355 (Elsevier. New York 1981).

National Institute for Health and Clinical Excellence (NICE): Clinical Knowledge Summaries: Corticosteroids - Oral. NICE; 2012. [http://www.cks.nhs. uk/corticosteroids_oral], Accessed February 20, 2013.

Menter A, Gottlieb A, Feldman SR, Van Voorhees AS, Leonardi CL, Gordon KB, Lebwohl M, Koo JY, Elmets CA, Korman NJ, Beutner KR. Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics. Journal of the American Academy of Dermatology. 2008 May 1;58(5):826-50.

Kerstjens HA, Brand PL, Hughes MD, Robinson NJ, Postma DS, Sluiter HJ, Bleecker ER, Dekhuijzen PR, de Jong PM, Mengelers HJ, Overbeek SE. A comparison of bronchodilator therapy with or without inhaled corticosteroid therapy for obstructive airways disease. New England Journal of Medicine. 1992 Nov 12;327(20):1413-9.

Grunberg SM. Antiemetic activity of corticosteroids in patients receiving cancer chemotherapy: dosing, efficacy, and tolerability analysis. Ann Oncol. 2007;18(2):233–240.

Mantovani G, Maccio A, Esu S, et al. Evidence that cisplatin induces serotonin release from human peripheral blood mononuclear cells and that methylprednisolone inhibits this effect. Eur J Cancer. 1996;32A(11):1983–1985.

Suzuki T, Sugimoto M, Koyama H, et al. Inhibitory effect of glucocorticoids on human-cloned 5-hydroxytryptamine3A receptor expressed in xenopus oocytes. Anesthesiology. 2004;101(3): 660–665.

Saag KG, Koehnke R, Caldwell JR, Brasington R, Burmeister LF, Zimmerman B, Kohler JA, Furst DE. Low dose long-term corticosteroid therapy in rheumatoid arthritis: an analysis of serious adverse events. The American journal of medicine. 1994 Feb 1;96(2):115-23.

Phipatanakul W, Mauger DT, Sorkness RL,Gaffin JM, Holguin F, Woodruff PG, et al.; Severe Asthma Research Program. Effects of age and disease severity on systemic corticosteroid responses in asthma. Am J Respir Crit Care Med 2017;195(11):14391448.

TantisiraKG,DamaskA,SzeflerSJ,Schuemann B, Markezich A, Su J, et al; SHARP Investigators. Genome-wide association identifies the T gene as a novel asthma pharmacogenetic locus. Am J Respir Crit Care Med 2012;185:1286-1291.

Nelson HS, Busse WW, deBoisblanc BP,Berger WE, Noonan MJ, Webb DR, et al. Fluticasone propionate powder; oral corticosteroid sparing effect and improved lung function and quality of life in patients with severe chronic asthma. J Allergy Clin Immunol 1999;103(2 Pt 1)267-275.

NiewoehnerDE,ErblandML,DeupreeRH,Collins D, Gross NJ, Light RW, et al. Effect of systemic glucocorticoids on exacerbations of chronic obstructive pulmonary disease.DepartmentofVeteransAffairsCooperative Study Group. N Engl J Med 1999; 340(25):1941-1947.

Aaron SD, Vandemheen KL, Hebert P,Dales R, Stiell IG, Ahuja J, et al. Outpatient oral prednisone after emergency treatment of chronic obstructive pulmonary disease. N Engl J Med 2003;348(26):26182625.

Huscher D, Thiele K, Gromnica-Ihle E, Hein G, Demary W, Dreher R, Zink A, Buttgereit F. Dose-related patterns of glucocorticoid-induced side effects. Annals of the rheumatic diseases. 2009 Jul 1;68(7):1119-24.

Held E, Ottervanger V, Petersen S, et al. Perioral dermatitis in children under steroid inhalation therapy. Ugeskr Laeger 1997; 157:7002–7003

Linder N, Kuint J, German B, et al. Hypertrophy of the tongue associated with inhaled steroid therapy in premature infants. J Pediatr 1995; 127:651–653

Hanania NA, Chapman KR, Kesten S. Adverse effects of inhaled corticosteroids. Am J Med 1995; 98:196–208

Barnes PJ, Pedersen S, Busse WW. Efficacy and safety of inhaled corticosteroids. Am J Respir Crit Care Med 1998; 157:S1–S53

Babu S, Samuel P. The effect of inhaled steroids on the upper respiratory tract. J Laryngol Otol 1988; 102:592–594

Williams AJ, Baghat MS, Stableforth DE, et al. Dysphonia caused by inhaled steroids: recognition of a characteristic laryngeal abnormality. Thorax 1983; 38:813–821

Dubus JC, Marguet C, Deschildre, et al. Local side effects of inhaled corticosteroids in asthmatic children: influence of drug, dose, age and device. Allergy. 2001; 56:944–948

Stanbury RM, Graham EM. Systemic corticosteroid therapy—side effects and their management. British Journal of Ophthalmology. 1998 Jun 1;82(6):704-8.

Richards RN. Side effects of short-term oral corticosteroids. Journal of cutaneous medicine and surgery. 2008 Mar;12(2):77-81.

Fisher DA. Adverse effects of topical corticosteroid use. Western journal of medicine. 1995 Feb;162(2):123.

Toozs-Hobson P, Cardozo L, Jacobs HS. Hormone replacement for all? BMJ 1996;313:350–2.

Dawson-Hughes B, Harris SS, Krall EA, et al. Effect of calcium and vitamin D supplementation on bone density in men and women 65 years of age or older. N Engl J Med 1997;337:670–6.

DOI: 10.26838/MEDRECH.2020.8.4.543
Published: 2021-08-16
How to Cite
Kanaparthi S. A review on the use of corticosteroids. Med. res. chronicles [Internet]. 2021Aug.16 [cited 2022Oct.3];8(4):357-62. Available from: https://medrech.com/index.php/medrech/article/view/515
Review Article